Understanding the Performance of Markets on 15th July 2020

July 15, 2020 09:15 PM AEST | By Team Kalkine Media

Google News:

Understanding the Performance of Markets on 15th July 2020

Recent News

Transurban Group (ASX:TCL): Navigating Growth in ASX200's Infrastructu...

Patronus Resources Expands Mertondale East Trend with New Discovery at...

Optus Faces $100 Million Penalty Amid Consumer Law Breach – ASX200 Foc...

ASX Stocks Show Mixed Momentum After Hitting 52-Week High

At the close of the trading session on 15^th July 2020, equity market of Australia ended in green. The benchmark index S&P/ASX200 witnessed a sharp rise of 111.8 points or 1.88% to 6052.9. Most of the sectors on ASX closed in green such as S&P/ASX 200 Consumer Staples (Sector), which moved up by 133.3 points to 13,116.8. S&P/ASX 200 Energy (Sector) settled at 7,440.4 with a rise of 67.9 points.

On ASX, the stock of CLINUVEL Pharmaceuticals Limited (ASX: CUV) went up by 6.803% to $23.550 per share. The share price of NRW Holdings Limited (ASX: NWH) stood at $1.700 per share, reflecting a rise of 6.25%.

Stock Performance (Source: ASX)

S&P/NZX50 stood at 11,611, indicating an increase of 1.01%. The share price of TRS Investments Ltd (NZX: TRS) rose by 50.00% to NZ$0.003 per share. Blackwell Global Holdings Limited’s stock (NZX: BGI) inched up by 21.88% and closed the trading session at NZ$0.039 per share. On the other hand, the stock of NZME Limited (NZX: NZM) plunged by 5.77% to NZ$0.245 per share.

Recently, we have written some crucial information on Empire Resources Limited (ASX:ERL), and the readers can view the information by clicking here.

CLINUVEL PHARMACEUTICALS LIMITED Rose by 6.803% on the Australian Securities Exchange.

CLINUVEL PHARMACEUTICALS LIMITED (ASX:CUV) recently revealed its second afamelanotide product in development, PRÉNUMBRA®. The company added that PRÉNUMBRA® is a liquid formulation of afamelanotide to be evaluated by CUV in clinical trials as a treatment for acute and systemic diseases. The second-generation product targets to provide prescribing physicians with dosing flexibility of the hormone analogue afamelanotide.

The company operates a profitable, cash flow positive pharmaceutical business with a clear objective to develop and deliver new products. CUV is planning to evolve into a diversified and integrated pharmaceutical business providing treatments to multiple patient groups. Moreover, the company’s financial performance has progressed through the Research & Development Phase into the Commercial Phase over time.

NRW Holdings Limited Ended in Green on 15^th July 2020

NRW Holdings Limited (ASX:NWH) recently notified the market that Mitsubishi UFJ Financial Group, Inc. has ceased to become a substantial holder in the company on 24^th June 2020. For the 10 months ended April 2020 (unaudited), the company reported record revenue amounting to $1.6 billion and EBITDA for the period stood at $177 million.

NWH added that the integration of BGC Contracting is progressing well, and all project teams are currently reporting through the NRW business structure. Considering the strong performance of the business, the company has paid an interim dividend of 2.5 cents per share on 9^th June 2020. The company is on track to meet the revenue guidance of $2 billion for FY20.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.